Jacqueline O'Toole1, Han Woo1, Nirupama Putcha1, Christopher B Cooper2, Prescott Woodruff3, Richard E Kanner4, Robert Paine4, Russell P Bowler5, Alejandro Comellas6, Karin F Hoth7, Jerry A Krishnan8, Meilan Han9, Mark Dransfield10,11, Anand S Iyer10, David Couper12, Stephen P Peters13, Gerard Criner14, Victor Kim14, R Graham Barr15, Fernando J Martinez16, Nadia N Hansel1, Michelle N Eakin1. 1. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Medicine and Department of Physiology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 3. Division of Pulmonary, Critical Care and Sleep, University of California at San Francisco, San Francisco, California. 4. Division of Pulmonary and Critical Care, University of Utah School of Medicine, Salt Lake City, Utah. 5. Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado. 6. Division of Pulmonary, Critical Care and Occupational Medicine, and. 7. Department of Psychiatry and Iowa Neuroscience Institute, University of Iowa, Iowa City, Iowa. 8. Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, Illinois. 9. Division of Pulmonary and Critical Care Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan. 10. Lung Health Center, Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 11. Birmingham Veterans Affairs Medical Center, Birmingham, Alabama. 12. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 13. Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina. 14. Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. 15. Division of General Internal Medicine, Columbia University Medical Center, New York, New York; and. 16. Cornell University School of Medicine, New York, New York.
Abstract
Rationale: Individuals with chronic obstructive pulmonary disease (COPD) have a high prevalence of depression, which is associated with increased COPD hospitalizations and readmissions. Objectives: Examine the impact of depressive symptoms compared with FEV1% on COPD morbidity. Methods: Using longitudinal data from individuals with COPD in the Subpopulations and Intermediate Outcome Measures in COPD Study, longitudinal growth analysis was performed to assess COPD morbidity by assessing differences in baseline 6-minute walk distance and patient reported outcomes (PROs) and their rate of change over time explained by depressive symptoms or lung function, as measured by Hospital Anxiety and Depression Scale or FEV1% respectively. PROs consisted of in-person completion of St. George's Respiratory Questionnaire, COPD Assessment Test, Functional Assessment of Chronic Illness Therapy Fatigue, and Modified Medical Research Council Dyspnea Scale measures. Results: Of the individuals analyzed (n = 1,830), 43% were female, 81% Caucasian with mean ± SD age of 65.1 ± 8.1, and 52.7 ± 27.5 pack-years smoking. Mean ± SD FEV1% was 60.9 ± 23.0% and 20% had clinically significant depressive symptoms. Adjusted models showed higher Hospital Anxiety and Depression Scale scores and lower FEV1% each were associated with worse PROs at baseline (P ⩽ 0.001). Depression accounted for more baseline variance in St. George's Respiratory Questionnaire, COPD Assessment Test, and Functional Assessment of Chronic Illness Therapy Fatigue than FEV1%, explaining 30-67% of heterogeneity. FEV1% accounted for more baseline variance in Modified Medical Research Council Dyspnea Scale and 6-minute walk distance than depression, explaining 16-32% of heterogeneity. Depressive symptoms accounted for 3-17% variance in change over time in PROs. In contrast, FEV1% accounted for 1-4% variance over time in PROs. Conclusions: Depression is more strongly associated with many PROs at baseline and their change over time compared with FEV1%. Recognizing and incorporating the impact of depressive symptoms into individualized care may improve COPD outcomes.
Rationale: Individuals with chronic obstructive pulmonary disease (COPD) have a high prevalence of depression, which is associated with increased COPD hospitalizations and readmissions. Objectives: Examine the impact of depressive symptoms compared with FEV1% on COPD morbidity. Methods: Using longitudinal data from individuals with COPD in the Subpopulations and Intermediate Outcome Measures in COPD Study, longitudinal growth analysis was performed to assess COPD morbidity by assessing differences in baseline 6-minute walk distance and patient reported outcomes (PROs) and their rate of change over time explained by depressive symptoms or lung function, as measured by Hospital Anxiety and Depression Scale or FEV1% respectively. PROs consisted of in-person completion of St. George's Respiratory Questionnaire, COPD Assessment Test, Functional Assessment of Chronic Illness Therapy Fatigue, and Modified Medical Research Council Dyspnea Scale measures. Results: Of the individuals analyzed (n = 1,830), 43% were female, 81% Caucasian with mean ± SD age of 65.1 ± 8.1, and 52.7 ± 27.5 pack-years smoking. Mean ± SD FEV1% was 60.9 ± 23.0% and 20% had clinically significant depressive symptoms. Adjusted models showed higher Hospital Anxiety and Depression Scale scores and lower FEV1% each were associated with worse PROs at baseline (P ⩽ 0.001). Depression accounted for more baseline variance in St. George's Respiratory Questionnaire, COPD Assessment Test, and Functional Assessment of Chronic Illness Therapy Fatigue than FEV1%, explaining 30-67% of heterogeneity. FEV1% accounted for more baseline variance in Modified Medical Research Council Dyspnea Scale and 6-minute walk distance than depression, explaining 16-32% of heterogeneity. Depressive symptoms accounted for 3-17% variance in change over time in PROs. In contrast, FEV1% accounted for 1-4% variance over time in PROs. Conclusions: Depression is more strongly associated with many PROs at baseline and their change over time compared with FEV1%. Recognizing and incorporating the impact of depressive symptoms into individualized care may improve COPD outcomes.
Authors: Prescott G Woodruff; R Graham Barr; Eugene Bleecker; Stephanie A Christenson; David Couper; Jeffrey L Curtis; Natalia A Gouskova; Nadia N Hansel; Eric A Hoffman; Richard E Kanner; Eric Kleerup; Stephen C Lazarus; Fernando J Martinez; Robert Paine; Stephen Rennard; Donald P Tashkin; MeiLan K Han Journal: N Engl J Med Date: 2016-05-12 Impact factor: 91.245
Authors: Abebaw Mengistu Yohannes; Hana Mülerová; Kim Lavoie; Jorgen Vestbo; Steve I Rennard; Emile Wouters; Nicola A Hanania Journal: J Am Med Dir Assoc Date: 2017-07-18 Impact factor: 4.669
Authors: Anne E Holland; Martijn A Spruit; Thierry Troosters; Milo A Puhan; Véronique Pepin; Didier Saey; Meredith C McCormack; Brian W Carlin; Frank C Sciurba; Fabio Pitta; Jack Wanger; Neil MacIntyre; David A Kaminsky; Bruce H Culver; Susan M Revill; Nidia A Hernandes; Vasileios Andrianopoulos; Carlos Augusto Camillo; Katy E Mitchell; Annemarie L Lee; Catherine J Hill; Sally J Singh Journal: Eur Respir J Date: 2014-10-30 Impact factor: 16.671
Authors: Anand S Iyer; Kristen E Holm; Surya P Bhatt; Victor Kim; Gregory L Kinney; Frederick S Wamboldt; Michael R Jacobs; Elizabeth A Regan; Hilary F Armstrong; Katherine E Lowe; Carlos H Martinez; Mark T Dransfield; Marilyn G Foreman; Gen Shinozaki; Nicola A Hanania; Robert A Wise; Barry J Make; Karin F Hoth Journal: J Psychosom Res Date: 2019-01-07 Impact factor: 3.006
Authors: Rebecca E Schane; Louise C Walter; Alexis Dinno; Ken E Covinsky; Prescott G Woodruff Journal: J Gen Intern Med Date: 2008-08-09 Impact factor: 5.128
Authors: Vincent S Fan; Scott D Ramsey; Nicholas D Giardino; Barry J Make; Charles F Emery; Phillip T Diaz; Joshua O Benditt; Zab Mosenifar; Robert McKenna; Jeffrey L Curtis; Alfred P Fishman; Fernando J Martinez Journal: Arch Intern Med Date: 2007-11-26
Authors: Marc Miravitlles; Heinrich Worth; Juan José Soler Cataluña; David Price; Fernando De Benedetto; Nicolas Roche; Nina Skavlan Godtfredsen; Thys van der Molen; Claes-Göran Löfdahl; Laura Padullés; Anna Ribera Journal: Respir Res Date: 2014-10-21